Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer

Elderly and poor performance status advanced non-small-cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate...

Descripción completa

Detalles Bibliográficos
Autores principales: Gridelli, C, Maione, P, Castaldo, V, Rossi, A
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2003
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394460/
https://www.ncbi.nlm.nih.gov/pubmed/14612886
http://dx.doi.org/10.1038/sj.bjc.6601387
_version_ 1782155421538058240
author Gridelli, C
Maione, P
Castaldo, V
Rossi, A
author_facet Gridelli, C
Maione, P
Castaldo, V
Rossi, A
author_sort Gridelli, C
collection PubMed
description Elderly and poor performance status advanced non-small-cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability.
format Text
id pubmed-2394460
institution National Center for Biotechnology Information
language English
publishDate 2003
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-23944602009-09-10 Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer Gridelli, C Maione, P Castaldo, V Rossi, A Br J Cancer Short Communication Elderly and poor performance status advanced non-small-cell lung cancer (NSCLC) patients often tolerate chemotherapy poorly. Special approaches are needed for these patient populations. Gefitinib (Iressa) was used in 59 elderly and/or unfit NSCLC pretreated patients participating in a compassionate use programme showing some activity and good tolerability. Nature Publishing Group 2003-11-17 2003-11-11 /pmc/articles/PMC2394460/ /pubmed/14612886 http://dx.doi.org/10.1038/sj.bjc.6601387 Text en Copyright © 2003 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Short Communication
Gridelli, C
Maione, P
Castaldo, V
Rossi, A
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
title Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
title_full Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
title_fullStr Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
title_full_unstemmed Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
title_short Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
title_sort gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer
topic Short Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2394460/
https://www.ncbi.nlm.nih.gov/pubmed/14612886
http://dx.doi.org/10.1038/sj.bjc.6601387
work_keys_str_mv AT gridellic gefitinibinelderlyandunfitpatientsaffectedbyadvancednonsmallcelllungcancer
AT maionep gefitinibinelderlyandunfitpatientsaffectedbyadvancednonsmallcelllungcancer
AT castaldov gefitinibinelderlyandunfitpatientsaffectedbyadvancednonsmallcelllungcancer
AT rossia gefitinibinelderlyandunfitpatientsaffectedbyadvancednonsmallcelllungcancer

Ejemplares similares